Apart from the above described beneficial effects that can contribute to the TRIM against COVID-19 by normalization of blood glucose and lipid levels, since β-glucan can reduce the insulin resistance which has been proven in human studies (17), a therapeutic TRIM response proving beneficial in COVID-19 will occur when β-glucans are employed as a prophylactic agents and the state of immunological tolerance which exists in individuals with obesity, diabetes and dyslipidemia can perhaps be reversed by these β-glucans (18). Here, PPIB is linked to obesity disorder.